Showing 1661-1670 of 7669 results for "".
- Michelson Diagnostics Launches Enhanced Software for VivoSight OCT Scannerhttps://practicaldermatology.com/news/20140219-michelson_diagnostics_launches_enhanced_software_for_vivosight_oct_scanner/2459339/Michelson Diagnostics recently launched its upgraded VivoSight Optical Coherence Tomography (OCT) scanner with a new software technology that provides additional features for dermatologists to investigate skin lesions such as non-melanoma skin cancer. The VivoSight OCT scanner enables the dermatolo…
- DEKA Medical Receives FDA Clearance for the Synchro REPLA:Yhttps://practicaldermatology.com/news/20140213-deka_medical_receives_fda_clearance_for_the_synchro_replay/2459343/The FDA cleared DEKA Medical, Inc.'s Synchro REPLA:Y, an aesthetic workstation dedicated, but not limited, to high speed stable long-term, or permanent hair reduction, treatment of PFB, treatment of benign pigmented lesions, treatment of wrinkles and photocoagulation of dermatological vascular lesi…
- Oculus Innovative Sciences Receives European CE Mark for Use of Microcyn to Treat Mild to Moderate Acnehttps://practicaldermatology.com/news/20140204-oculus_innovative_sciences_receives_european_ce_mark_for_use_of_microcyn_to_treat_mild_to_moderate_acne/2459350/Oculus Innovative Sciences, Inc. received European CE Mark for the Microcyn-based GramaDerm Solution and GramaDerm Hydrogel. Both products are intended for use in the topical treatment of mild to moderate acne and are designed to complement other acne treatments. The new CE M…
- Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Millionhttps://practicaldermatology.com/news/20140203-valeant_pharmaceuticals_to_acquire_precision_dermatology_for_475_million/2459351/Valeant Pharmaceuticals International, Inc. has entered into a definitive agreement to acquire PreCision Dermatology, Inc. for $475 million in cash, plus an additional $25 million payable upon the achievement of a sales-based milestone. PreCision develops and markets high qual…
- Valeant Pharmaceuticals Announces FDA Approval of Retin-A Micro Microsphere 0.08%https://practicaldermatology.com/news/20140131-valeant_pharmaceuticals_announces_fda_approval_of_retin-a_micro_microsphere_008/2459353/The FDA approved Valeant Pharmaceuticals' Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) Gel microsphere 0.08% for the topical treatment of acne vulgaris. "We are very pleased that the FDA has approved our new strength of Retin-A Micro as this gives health care providers an…
- Valeant Pharmaceuticals Completes Acquisition of Solta Medicalhttps://practicaldermatology.com/news/20140127-valeant_pharmaceuticals_completes_acquisition_of_solta_medical/2459359/Valeant Pharmaceuticals International, Inc. completed its acquisition of Solta Medical, Inc. at a price of $2.92 per share in cash, or approximately $250 million in the aggregate. On January 23, 2014, Valeant successfully completed the tender offer for all outstanding shares …
- DERM: The Dermatology Essential Resource Meeting Announcedhttps://practicaldermatology.com/news/20140122-derm_the_dermatology_essential_resource_meeting_announced/2459364/DERM 2014: The Dermatology Essential Resource Meeting will be held July 24-27 at the Encore in Las Vegas. This new, accredited conference focuses exclusively on clinically relevant and practical educational needs of NPs and PAs in dermatology, according to organizers. The mission of the program is…
- FDA Approves Celluma as OTC Light Therapy Device to Treat Acne and Morehttps://practicaldermatology.com/news/20140121-fda_approves_celluma_as_otc_light_therapy_device_to_treat_acne_and_more/2459366/The FDA approved BioPhotas, Inc.'s Celluma as an Over-The-Counter (OTC) light therapy device. The Celluma, a proprietary biophotonic medical device, had been previously cleared in 2013 for six separate Indications-For-Use on a Prescription basis, including the treatment of acn…
- Practical Dermatology® Magazine Names Neal Bhatia, MD, FAAD Co-Chief Medical Editorhttps://practicaldermatology.com/news/20140117-practical_dermatology_magazine_names_neal_bhatia_md_faad_co-chief_medical_editor/2459367/Neal Bhatia, MD, FAAD, San Diego-based dermatologist and well known lecturer and author, has been named Co-Chief Medical Editor of Practical Dermatology® magazine from Bryn Mawr Communications III, LLC. Now in it's 11th year of publication, Practical Dermatology® magazine continues to deliver depe…
- Injectable Methotrexate Product Now Availablehttps://practicaldermatology.com/news/20140117-injectable_methotrexate_product_now_available/2459369/For patients who do not tolerate oral methotrexate for psoriasis, a new recently approved injectable methotrexate product is now available from Antares Pharma. Approved in October 2013 for the subcutaneous methotrexate product for once weekly self-administration, Otrexup is indicated for use in adu…